12:00 AM
 | 
Dec 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PH-10: Preliminary Phase II data

Preliminary data from an open-label, U.S. Phase II trial in 18 evaluable patients showed that PH-10 improved EASI in 94% of patients with no significant safety issues observed. Patients...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >